Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.An interim safety analysis of Nymox Pharmaceutical's phase II trial of the company's lead drug candidate NX-1207 to treat benign prostatic hyperplasia has revealed no serious drug side effects.
Subscribe to our email newsletter
Benign prostatic hyperplasia afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.
According to the company, two previously completed trials of the drug in the US have shown excellent efficacy without serious side effects. The company’s large phase II trial is expected to be completed later this year.
In the completed phase I-II trials to date, the subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. Subjects that were followed for up to two years post-treatment showed even further statistically significant symptom improvement.